30
Participants
Start Date
July 18, 2017
Primary Completion Date
March 31, 2019
Study Completion Date
August 19, 2020
Tislelizumab
Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Cisplatin
Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
5-FU
Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
Oxaliplatin
Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
Capecitabine
Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Fifth Medical Center of Pla General Hospital, Beijing
Harbin Medical University Cancer Hospital, Harbin
Northern Jiangsu Peoples Hospital, Yangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Xian Jiaotong University, Xi'an
Lead Sponsor
BeiGene
INDUSTRY